Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Gall Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Thornton

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

8820 Huron St
Thornton, CO 80260
P: (303) 386-7622

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Lakewood

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

11750 W 2nd Place, Suite 160
Lakewood, CO 80228
P: (303) 430-2700

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Littleton

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

22 W Dry Creek Circle
Littleton, CO 80120
P: (303) 730-4700

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Lone Tree

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

10107 RidgeGate Parkway, Suite 200
Lone Tree, CO 80124
P: (303) 925-0700

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Longmont

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

1760 E. Ken Pratt Blvd. Suite 302
Longmont, CO 80504
P: (303) 684-1900

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, CO 80220
P: (303) 321-0302

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

1800 N Williams St, Suite 200
Denver, CO 80218
P: (303) 388-4876

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Englewood

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

499 E. Hampden Ave.
Suite 450
Englewood, CO 80113
P: (303) 740-8200

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Colorado Springs

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

2312 N Nevada Ave, Suite 400
Colorado Springs, CO 80907
P: (719) 577-2555

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

4715 Arapahoe Avenue
Boulder, CO 80303
P: (303) 385-2068

More Details View Practice Page
1 2

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.